Development and validation of a questionnaire to self-assess patient knowledge of direct oral anticoagulants (KODOA-test)

Corina Metaxas¹
Valerie Albert¹
Matthias Stahl²
Kurt E Hersberger¹
Isabelle Arnet¹

¹Department of Pharmaceutical Sciences, Pharmaceutical Care Research Group, University of Basel, Basel, Switzerland; ²Department of Internal Medicine, Kantonsspital Basel-Land, Bruderholz, Switzerland

Objective: Few studies have examined associations between patient knowledge of direct oral anticoagulants (DOAC) and clinical outcomes, mostly because of the lack of validated questionnaires for assessing knowledge. The aim of this study was to develop and validate a questionnaire to self-assess knowledge of DOAC.

Methods: Twelve anticoagulation experts participated in the questionnaire development process to ensure content validity. The Knowledge Of Direct Oral Anticoagulants (KODOA)-test was submitted to patients on DOAC and to pharmacists to assess construct validity. Responsiveness was evaluated after educational counseling. Test–retest reliability was assessed to ensure stability over time, and Cronbach’s α was calculated for internal reliability. Index of difficulty and item discrimination (D-value) were calculated to assess the performance of single items.

Results: The KODOA-test contains 15 items with multiple-choice answers. Each correct answer scores 1 point (max. score of 15). The KODOA-test was administered to 32 patients on DOAC and 28 pharmacists. Pharmacists scored significantly higher than patients at baseline (median score 13.3 vs 10.0; p < 0.001), supporting construct validity. Patient scores increased significantly after educational counseling (median score 11 [interquartile range 2] vs 14 [interquartile range 3]; p < 0.001). Test–retest and Cronbach’s α were acceptable with a Pearson’s correlation of 0.8 and an α of 0.67. The index of difficulty for most items was satisfactory (0.38–0.72) and the mean D-value was 42.5%.

Conclusion: The KODOA-test is a brief, valid, and reliable knowledge self-assessment questionnaire that may be used in clinical trials to investigate associations between knowledge increase and patient-related outcomes.

Keywords: patient knowledge, direct oral anticoagulants, questionnaire development, adherence, validation

Introduction
After a 50 years use of vitamin K antagonists (VKAs) as oral anticoagulant agents (OACs), a new class of substances with different mechanism of action, the direct oral anticoagulants (DOAC), also called non-vitamin K oral anticoagulants, has been developed. DOAC are recommended for the prevention and treatment of thromboembolic diseases such as for the long-term prevention or treatment of thrombosis¹ and for the prophylaxis of stroke and systemic embolism in nonvalvular atrial fibrillation (AF).² Controlling blood values is needed to maintain appropriate anticoagulation with VKAs due to the narrow therapeutic window, which makes the treatment challenging. In contrast to VKA, DOAC do not require routine monitoring, have a fixed dose
regimen, and possess no restriction on dietary consumption of vitamin K-containing food. Therefore, DOAC seem more convenient for patients than therapy with VKAs. In practice, use of DOAC to treat AF is increasing. However, due to their short half-life, DOAC’s anticoagulant effect is likely to be rapidly reduced after the omission of one dose when no counterbalancing action is undertaken. Thus, DOAC’s daily intake requires a strict timing adherence to ensure appropriate therapeutic coverage. Because DOAC do not require consultations for monitoring, the opportunity to discuss aspects of adherence with the patient during such encounters will be missing. Consequently, other ways of insuring adherence to DOAC are required.

Improvement of knowledge and adherence in patients on OACs, in particular DOAC, is needed. For VKAs, enhanced patient knowledge of OACs and the underlying disease was associated with improved long-term adherence or better therapeutic outcomes. To study associations between knowledge and adherence, validated questionnaires are needed to assess patient knowledge of DOAC. To date, various questionnaires exist that assess OAC knowledge. However, only a few have been psychometrically validated, such as the Oral Anticoagulation Knowledge (OAK), the Anticoagulation Knowledge Assessment (AKA) test and the recently published Anticoagulation Knowledge Tool (AKT). Only AKT can be used for VKAs and DOAC. To our knowledge, there is no specific knowledge assessment questionnaire for DOAC available.

The objective of this study was to develop and validate a questionnaire to self-assess patient knowledge of DOAC.

Methods

Trial design

The study was initiated by the Pharmaceutical Care Research Group of the University of Basel. The study was conducted in accordance with the Declaration of Helsinki and has been registered at ClinicalTrials.gov ID NCT03124654. The study was approved by the regional ethic committee (Ethikkommission Nordwest- und Zentralschweiz UBE15/126). All patients gave written informed consent.

Development of the Knowledge Of Direct Oral Anticoagulants (KODOA)-test

Literature search

A systematic literature search in Medline and Embase was conducted in March 2015 to retrieve published questions assessing patient knowledge of anticoagulation treatment. The search strategy was performed with truncated terms: “Patient* education*” AND “Anticoagulant*” OR “Anticoagulation treatment*” OR “Knowledge” and the limits: English language, human, published from 2005 to March 2015. Abstracts were screened and full texts were retrieved. Two authors (CM and VA) extracted the items of interest. Items regarding VKAs were adapted to DOAC if applicable. Consensus was reached by discussion. Swiss summaries of Product Characteristics, the Updated European Heart Rhythm Association (EHRA) Practical Guide on the use of non-vitamin K antagonist anticoagulants, the patient guide for taking DOAC from a cardiology patient page and patient information leaflets of the 4 in Switzerland authorized DOAC were used to retrieve additional content. Items were grouped into the 9 educational topics as follows: 1) underlying disease; 2) risk–benefit of treatment; 3) mode of action; 4) application and treatment adherence; 5) accessing health care providers; 6) relevant blood tests; 7) medication interactions; 8) diet and lifestyle; and 9) self-care.

Item reduction and content validity

A panel of experts was created with 12 health care professionals (HCP; 4 nurses, 4 pharmacists, and 4 physicians) who had experience with DOAC patients. They selected the relevant items for patient knowledge of DOAC and determined the extent to which the items represent the construct of interest (content validity).

The item reduction occurred with an online survey (2 rounds) followed by a focus group discussion. The 9 educational topics (first round) and the single items (second round) were ranked in descending order (first = most relevant topic, last = most irrelevant topic). The focus group discussion aimed at defining which items had to be included in the questionnaire by defining a threshold above which the items were perceived as relevant for patient knowledge. Discussion and setting threshold occurred by voting until a consensus was found (unanimity). The session was recorded and transcribed verbatim.

Answer format

Answers to the items were developed as multiple-choice format because this is the most appropriate and efficient form for assessing cognitive knowledge. One correct and 2 incorrect response alternatives were adapted from the original article when available or were newly created. A score was defined as 1 for a correct response and 0 for an incorrect or no response. Confidence about the given response was assessed with a single question with a yes/no answer option.
Educational manual with correct answers as counseling guide
A manual with referenced correct answers and background information about the reason for correctness was generated in order to standardize the education provided to patients. The manual is not supposed to be given to patients. The manual starts with an instruction section about how to dispense the educational counseling. The HCP is invited to discuss systematically each question with the patient. Whenever the patient gave a wrong answer or ticked the “to be uncertain about the question” option, HCPs are instructed to give the correct answer with background information according to the manual. Then HCPs should ask if the issue is clear or if the patient needs further information. When every question of the KODOA-test has been discussed as described, HCPs should ask the patient if there are any unanswered questions about their DOAC. Although not part of the questionnaire, information about intake time of DOAC was added to cover all instructions needed to counsel. The manual was used by two investigators (CM and VA) during counseling sessions.

Pilot testing
Comprehension and readability of the finalized KODOA-test was presented to the experts who participated in the focus group discussion and 5 patients who were not included in the validation study. They rated structure, content, comprehension, and response alternatives by writing commentaries in free text. Adaptions were made accordingly.

Validation of the KODOA-test
Patient eligibility
Patients were eligible if they filled a prescription for DOAC (rivaroxaban, edoxaban, dabigatran, or apixaban) in a community pharmacy or if a DOAC was present in their medical record, if they suffered from AF, deep vein thrombosis, or pulmonary embolism, if they were ≥18 years old, and if they were able to give written informed consent in German. Patients with an orthopedic indication for DOAC, with dementia, or unable to provide written and/or oral understanding in German were excluded from the study.

Data collection
A selection of community pharmacists engaged as experts for the state exams of the University of Basel were invited to participate in the research and asked to distribute this invitation to all community pharmacists with whom they were working. Three dedicated community pharmacies located in Basel City and Münchenstein accepted to serve as recruiting places. Pharmacy staff asked patients with a prescription for DOAC to participate in the study and handed out the patient information and the informed consent forms. Patients who agreed to participate fixed 2 appointments within 2 weeks at the community pharmacy.

Patients filled in the KODOA-test 4 times. During the first appointment at the community pharmacy (T1), feasibility and acceptability were also assessed. Immediately after patients filled in the KODOA-test, they rated on a 4-point Likert scale structure, readability and time to fill in the questionnaire, comprehensibility and ambiguity of the items, and the available answer options.

During the second appointment at the community pharmacy, patients filled in the KODOA-test again (T2) and received educational counseling according to the wrong given answers. Immediately after, patients filled the KODOA-test a further time (T2 + edu). Test–retest was assessed with answers from T1 and T2, and responsiveness with answers from T2 and T2 + edu.

Approximately 2 weeks after T2, patients received the KODOA-test by post (with a paid reply envelope) and filled it at home (T3) to assess sustainability of the educational counseling. Patient follow-up by the treating physician (general practitioner or cardiologist) took place as usual.

Patient characteristics were obtained through written survey at T1 and included demographic (age, gender, educational background, and duration of DOAC therapy) characteristics and 3 health literacy questions: difficulties to understand written information about medication (yes/neural/no); difficulties to understand verbal information about medication (yes/neural/no); confidence when filling out forms (yes/neural/no). One question assessed self-estimated knowledge of DOAC with the answer options bad, moderate, good, or excellent. At T3, patients were asked to rate following statement on a five-point Likert scale: “After educational counseling I know more about my DOAC” (1= I do agree; 5= I do not agree).

A personal letter was sent to 29 pharmacists asking them to answer the KODOA-test without consulting additional media and to return it using a prepaid reply envelope.

Statistical methods
Where appropriate, frequencies, mean, and standard deviations; or median and interquartile ranges (IQR) are presented. Kruskal–Wallis test was used to compare numerical variables.
between 4 groups. All data were entered and analyzed using SPSS statistical package version 24.0 (IBM Corporation, Armonk, NY, USA), and p-values <0.05 were considered significant.

Validation parameters
Construct validity was tested with the method of contrasted groups. Construct validity would be confirmed if the median test score of pharmacists was significantly higher than median test score of patients at T1. Mann–Whitney U-test was used to compare numerical data between groups. At T2, patients received educational counseling about DOAC and responsiveness of the KODOA-test was tested. Median test scores before (T2) and after educational counseling (T2 + edu) about DOAC were compared using Wilcoxon test.

The test–retest method was used to demonstrate the stability of the questionnaire over time. Pearson’s correlation coefficient was calculated between the test scores from T1 to T2 and T2 + edu to T3. Additionally, internal consistency or reliability was assessed using Cronbach’s α, which indicates whether each item of a scale is appropriate for assessing the underlying concept of its scale. Values for Cronbach’s α range between 0 and 1; the closer they are to 0, the less the items are related to one another. Values between 0.5 and 0.7 are the minimal requirement to indicate satisfactory internal consistency.

Index of difficulty and item discrimination (D-value) were calculated to assess performance of single items. The index of difficulty is defined as the proportion of patients answering the item correctly (=number of correct responses/total number of responses). An item with an index of difficulty >0.75 is deemed to be too frequently answered correctly. Item discrimination (D-value) tests how well an item discriminates between people who have a low and high knowledge score. A D-value is calculated by subtracting for each item the proportion of respondents answering correctly in the lowest quartile from those answering correctly in the highest quartile, aiming for a mean D-value of 50%.

Results
Out of 45 compiled items, the expert panel selected 15 to be important for knowledge of DOAC. The 15 items were derived from the educational topics “Application and treatment adherence” (5 items, number [nb.] 3, 5–8), “Risk–benefit of treatment” (2 items, nb. 2, 4), “Accessing health care providers” (2 items, nb. 12, 13), “Self-care” (2 items, nb. 9, 15), “Relevant blood tests” (1 item nb. 14), “Medication interactions” (2 items, nb. 10, 11), and “Mode of action” (1 item, nb. 1). Two versions of the KODOA-test were developed, 1 for patients with AF and 1 for patients with deep vein thrombosis or pulmonary embolism. The 2 versions differed in the answer options in items 2, 3, and 4, depending on the underlying disease (Figure S1).

Out of 67 invited patients, 32 participated (Table 1). They were prescribed either rivaroxaban (84.4%) or apixaban (15.6%). Mean duration of DOAC use was 1.8±1.7 years. Patients had mandatory education (n=3), technical/vocational education (n=11), a higher school certificate (n=11), University degree (n=4), or did not give any information (n=3). A majority of patients stated to have no difficulties to understand written and verbal information about medication and were found to be confident when filling out forms (Table 1). One patient (3.1%) was lost to follow-up (T3) and 1 patient did not fill in the knowledge question for follow-up evaluation.

Feasibility was confirmed. Mean time to fill in the KODOA-test was 7.8±3.0 minutes, and patients were satisfied with the structure, readability, comprehension, and time to fill in the questionnaire (Figure 1).

Twenty-eight pharmacists (34±9 years, 8±9 years working experience) filled in the KODOA-test. Median test score of community pharmacists (13.0 [IQR 1]) was significantly higher compared to test score of patients (10 [IQR 4]) at T1 (U-Test: p<0.001). Median test score of patients at T2 was 11 (IQR 2), and increased significantly to 14 (IQR 3) after educational counseling (Wilcoxon: p<0.001).

Educational counseling about DOAC lasted 14±7 minutes. The median number of items whose answers were correct and ticked as confident was calculated. This number increased from 9 (IQR 3) at T2 to 14 (IQR 1) after educational counseling at T2 + edu (Wilcoxon: p<0.001).

Reliability of the KODOA-test was demonstrated. Test–retest reliability between T1 and T2 (r=0.800, p<0.001; 12 day mean duration between the tests) and between T2 + edu and T3 was confirmed (r=0.644, p<0.001; 17 days mean duration between the tests) (Table 2). Internal consistency was acceptable (Cronbach’s α=0.67). Cronbach’s α was found to increase slightly (0.673–0.678) if items 3, 5, 6, or 11 were excluded (Table 3). The index of difficulty for most items was satisfactory (0.38–0.72) (Table 3). The mean D-value was 42.5%.

There was no relationship between KODOA-test scores at T1 and patient self-estimated knowledge of DOAC (Table 1). Patients with higher self-estimated knowledge tended to answer with more confidence (Table 1). At T3, all patients agreed that they knew more about their DOAC after having received educational counseling.
Table 1 Patient and pharmacists characteristics at T1 (baseline)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Patients (n=32)</th>
<th>Pharmacists (n=28)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female (%)</td>
<td>65.5</td>
<td>89.0</td>
</tr>
<tr>
<td>Age (years; mean ± SD)</td>
<td>73±9</td>
<td>34±9</td>
</tr>
<tr>
<td>Indication (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AF</td>
<td>62.5</td>
<td></td>
</tr>
<tr>
<td>Deep vein thrombosis/pulmonary embolism</td>
<td>37.5</td>
<td></td>
</tr>
<tr>
<td>Duration of therapy (years, mean ± SD)</td>
<td>1.8±1.7</td>
<td></td>
</tr>
<tr>
<td>Comprehension of written information about medication (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Without difficulties</td>
<td>46.8</td>
<td></td>
</tr>
<tr>
<td>Neutral</td>
<td>21.9</td>
<td></td>
</tr>
<tr>
<td>With difficulties</td>
<td>31.3</td>
<td></td>
</tr>
<tr>
<td>Comprehension of verbal information about medication (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Without difficulties</td>
<td>75.0</td>
<td></td>
</tr>
<tr>
<td>Neutral</td>
<td>12.5</td>
<td></td>
</tr>
<tr>
<td>With difficulties</td>
<td>12.5</td>
<td></td>
</tr>
<tr>
<td>Confidence when filling out forms (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Confidence</td>
<td>93.8</td>
<td></td>
</tr>
<tr>
<td>No confidence</td>
<td>6.2</td>
<td></td>
</tr>
<tr>
<td>Self-estimated knowledge (% of patients [number of patients])</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bad</td>
<td>9.4 (n=2)</td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td>31.3 (n=10)</td>
<td></td>
</tr>
<tr>
<td>Good</td>
<td>53.0 (n=17)</td>
<td></td>
</tr>
<tr>
<td>Excellent</td>
<td>6.3 (n=2)</td>
<td></td>
</tr>
<tr>
<td>KODOA-test scores (mean ± SD)</td>
<td>11.0±4.4</td>
<td>8.2±2.4</td>
</tr>
<tr>
<td>Number of ticks “being certain about the correctness of the given answer” (mean ± SD)</td>
<td>10.9±2.1</td>
<td>10.5±3.5</td>
</tr>
</tbody>
</table>

Abbreviations: AF, atrial fibrillation; KODOA, Knowledge Of Direct Oral Anticoagulants; SD, standard deviation.

Discussion

The KODOA-test was confirmed to be feasible, comprehensive, reliable, and valid to self-assess patient knowledge of DOAC. Furthermore, the KODOA-test is responsive to change. Content validity was ensured by a developing process with experts of different professions taking care of patients undergoing anticoagulation therapy in their daily practice. Construct validity was supported by significant differences...
in scores between patients and pharmacists. Finally, the KODOA-test was responsive to educational counseling on DOAC, supporting construct validity.

Patients were able to complete the test within 8 minutes, and rated this time as acceptable. Compared to other assessment questionnaires for knowledge of OAC therapy, the KODOA-test is relatively brief. The AKT and AKA assessment questionnaires need 10–15 and 20 minutes to be filled in, respectively.11,12

The index of difficulty of most items and mean D-value was satisfactory. Although 6 items showed a poor level of difficulty, they were retained because they are related to core information about DOAC therapy, such as name, treatment duration, or whom to ask in case of pharmaceutical questions. The KODOA-test showed moderate internal consistency, with a Cronbach’s α of 0.67. The obtained Cronbach’s α value is likely a result of the multifactorial nature of the KODOA-test because it consists of items derived from several educational topics. Omission of single items had minimal effect on Cronbach’s α. The KODOA-test included very easy items and very difficult items. Despite the fact that such grade of difficulty tends to decrease the internal consistency of the scale,21 HCPs need basic questions on the medication used by the patient such as dosing frequency. Finally, a low Cronbach’s α might be explained by the shortness of KODOA-test with 15 questions, since internal consistency increases as test length increases.22 Therefore, an α of 0.67 seems acceptable.

Stability over time was confirmed by test–retest correlation above the threshold of 0.7, which indicates adequate reliability.23 The mean time between test and retest was 12 days. Recommendations for interval between 2 identical tests vary between 2 days21 and 3 months.24 Two studies investigating knowledge of anticoagulation with questionnaires had longer intervals of 2–3 months for the retest,10,12 and 2 further studies on knowledge of nutrition had intervals of 2 weeks.25,26 We selected a short time interval based on ethical considerations, because patients with deficient knowledge should be corrected as soon as possible in order to avoid life-threatening situations. Knowledge scores remained high after approximately 2 more weeks, demonstrating the sustainability of the educational counseling. In addition, patients agreed uniformly that their knowledge had increased. Nevertheless,

| Table 2 Mean KODOA-test scores, ie, correctly answered questions (± SD) at T1, T2, T2 + edu (after educational counseling), and T3 |
|-----------------|------------|-----------------|
| Visit           | Patients (n=32) | Pharmacists (n=28) | p-value |
| T1              | 10.03±2.7     | 13.3±1.0         | <0.001  |
| T2              | 10.06±2.1*    | NA               |         |
| T2 + edu        | 13.9±1.2*     | NA               |         |
| T3              | 13.1±1.7      | NA               |         |

Notes: *Mean duration between tests: 12 days. NA: not applicable; SD, standard deviation; T1, first appointment at the community pharmacy; T2, second appointment at the community pharmacy; T3, 2 weeks after T2. 

| Table 3 Content and psychometric properties of the KODOA-test items |
|-----------------|-----------------|-----------------|-----------------|
| Item number | Content Patients with correct answer (%) | Index of difficulty | Item discrimination if item is omitted | Cronbach’s α |
| 1             | Name of the DOAC 93     | 0.94            | 18.2           | 0.660        |
| 2             | Duration of therapy 90  | 0.91            | 18.2           | 0.669        |
| 3             | Dosing frequency 81     | 0.81            | 45.5           | 0.673        |
| 4             | Indication for DOAC 93  | 0.94            | 18.2           | 0.656        |
| 5             | What to do if uncertain whether last dose was ingested 43 | 0.44            | 47.7           | 0.673        |
| 6             | What to do in case of a missed dose 37 | 0.38            | 35.2           | 0.678        |
| 7             | What to do in case of double dosing 37 | 0.38            | 56.8           | 0.645        |
| 8             | Does the DOAC work when vomiting immediately after ingestion 37 | 0.38            | 81.8           | 0.640        |
| 9             | Most frequent side effect 59 | 0.59            | 47.7           | 0.647        |
| 10            | Safest OTC analgesic with DOAC 53 | 0.53            | 47.7           | 0.640        |
| 11            | Whom to ask about safe OTC 90 | 0.91            | 5.7            | 0.673        |
| 12            | When to inform others about DOAC therapy 87 | 0.88            | 27.3           | 0.655        |
| 13            | Recognition of emergencies 65 | 0.66            | 81.8           | 0.605        |
| 14            | How often to visit the doctor for lab monitoring 59 | 0.59            | 51.1           | 0.652        |
| 15            | Carrying an anticoagulation card 71 | 0.72            | 54.5           | 0.638        |

Abbreviations: DOAC, direct oral anticoagulants; KODOA, Knowledge Of Direct Oral Anticoagulants; OTC, over the counter.
further follow-ups could be useful to maintain a high level of knowledge. The state of the art currently in Switzerland and in many other countries is silo interventions from several HCPs. It would be best practice to share information and questionnaire results between HCPs.

The majority of patients rated their knowledge of DOAC at baseline as good or excellent. However, this self-estimation did not correspond to KODOA-test scores, suggesting that patients both overestimate and underestimate their knowledge. Consequently, self-estimation of knowledge with a single question should be taken with caution. Further, asking for confidence when answering the item is subject to the same under- and overestimation. However, because of the low number of patients in the bad and excellent self-estimated knowledge groups, this finding needs further investigation.

Interestingly, patients’ scores after educational counseling were still below the maximum, with an average of 1.9 erroneous answers. The items concerning safety issues (missed dose, double dosing, vomiting) seem difficult to remember. HCPs should be aware that some pharmacological concepts are more demanding than others.

Previous studies observed an increase of knowledge of OAC therapy following education. However, only one study included patients on DOAC, but knowledge assessment methods were not developed for patients on DOAC therapy. In a recent study, the development of an OAC knowledge questionnaire was reported. The AKT contains 20 items applicable for DOAC patients and 8 additional items for VKA patients. Overall, the AKT seems to be a valid and reliable questionnaire to measure patient knowledge of oral anticoagulants. However, it is not reported whether the AKT is responsive to change, and scoring seems more complicated as with the KODOA-test. In light of these inconveniences, KODOA-test is likely to be easier to use in patient studies.

Our study has several strengths. First, we followed an evidence-based approach to select items. We coupled a literature search to educational theory to reduce the number of items to the minimum needed to assess knowledge. Second, we used the most recent publication such as the EHRA guidelines to cover exhaustively the characteristics of anticoagulation therapy. Third, we selected experts in all fields of the health care professions to determine the relevant items needed in a self-assessment questionnaire. Fourth, we tested pharmacists as representatives of HCPs. We are confident that similar knowledge results would have been obtained with doctors and nurses. Finally, we developed a manual with answers to obtain standardization of educational counseling. By doing so, we offer a fast and efficient way of counseling to all HCPs who provide information for patients.

We acknowledge some limitations. First, 52.3% of the patients refused to participate in the study. Time consumption (ie, 2 visits at the community pharmacy) was likely the reason of this moderate acceptance rate, rather than a low acceptability to answer the KODOA-test. Second, the relatively small number of subjects may limit the ability to generalize results to all patients on DOAC. Importantly, sample size was adequate to show that the KODOA-test is responsive to change and that construct validity is given (data not shown). Third, this study included elderly Swiss German speaking patients with an indication to AF or deep vein thrombosis/pulmonary embolism and taking rivaroxaban or apixaban, that is, only 2 of the 4 commercially available DOACs in Switzerland. Because the KODOA-test targets DOAC knowledge in general, that is, independently of the anticoagulant agent, we cannot think that patients on other anticoagulants (ie, edoxaban or dabigatran) or in another setting (ie, after surgery) would have answered differently. Applicability of the KODOA-test in other settings should nevertheless be investigated in a further study. Finally, the multiple-choice format permits guessing, which may have increased scores in both the patient and pharmacist groups.

Conclusion
The KODOA-test showed to be valid and reliable in Swiss German speaking elderly outpatients taking DOAC. The application of the KODOA-test in other populations needs confirmation by further research. To our knowledge, the KODOA-test is the first validated questionnaire specific for patients taking DOAC that is responsive to educational counseling. Therefore, the KODOA-test could be used in clinical trials where associations between knowledge of DOAC and adherence or clinical outcomes are of interest.

Acknowledgment
We would like to thank all experts participating in the development process of the KODOA-test, the 3 community pharmacies for patient recruitment, and all patients and pharmacists for participating in the validation study. We thank Susanne Habegger for her contributions to the literature review and Sonja Luginbühl for the organization of the focus group discussion and KODOA-test piloting. We thank William Caddy for proofreading. The study was developed as an investigator-initiated project by the Pharmaceutical Care Research Group, University of Basel, and received partial
financial support by Bayer AG. The funders had no role in the
design, conduct, analyses, or writing of this study or in the
decision to submit for publication.

Disclosure
The authors report no conflicts of interest in this work.

References
1. Robertson L, Kesteven P, McCaslin JE. Oral direct thrombin inhibitors
or oral factor Xa inhibitors for the treatment of pulmonary embolism.
the management of atrial fibrillation developed in collaboration with
oral anticoagulation agents in anticoagulant naive atrial fibrillation
4. Rodríguez-Bernal CL, Hurtado I, García-Sempere A, Peiró S, Sanfélix-
Gimeno G. Oral anticoagulants initiation in patients with atrial fibrilla-
2017;8:63.
5. Mani H, Lindhoff-Last E. New oral anticoagulants in patients with
nonvalvular atrial fibrillation: a review of pharmacokinetics, safety,
efficacy, quality of life, and cost effectiveness. Drug Des Devel Ther.
2014;8:789–798.
attitude, education, and knowledge about oral anticoagulation therapy
among patients with atrial fibrillation in Europe: result of a self-
assessment patient survey conducted by the European Heart Rhythm
7. Wang Y, Kong MC, Lee LH, Ng HJ, Ko Y. Knowledge, satisfaction,
and concerns regarding warfarin therapy and their association with
warfarin adherence and anticoagulation control. Thrombosis Res.
8. ClarkeSmith DE, Pattison HM, Lip GYH, Lane DA. Educational inter-
vention improves anticoagulation control in atrial fibrillation patients:
9. Barcellona D, Contu P, Marongiu F. Patient education and oral anti-
10. Zeolla MM, Brodeur MR, Dominelli A, Haines ST, Allie ND. Develop-
ment and validation of an instrument to determine patient knowl-
11. Briggs AL, Jackson TR, Bruce S, Shapiro NL. The development and
performance validation of a tool to assess patient anticoagulation
12. Obamiro KO, Chalmers L, Bereznicki LR. Development and valida-
Rhythm Association Practical Guide on the use of non-vitamin K
antagonist anticoagulants in patients with non-valvular atrial fibrillation.
Europace. 2015;17(10):1467–1507.
the non-vitamin K antagonist oral anticoagulants for atrial fibrillation.
15. Wofford JL, Wells MD, Singh S. Best strategies for patient education
about anticoagulation with warfarin: a systematic review. BMC Health
Serv Res. 2008;8:40.
17. Downing SM. Assessment of knowledge with written test forms. In:
Norman GR, van der Vleuten CPM, Newble DL, editors. International
Handbook of Research in Medical Education. Vol 2. Dordrecht, The
18. Westen D, Rosenthal R. Quantifying construct validity: two simple
Health Services. 2nd ed. Buckingham, UK: Open University Press;
2002.
21. Streiner EL, Norman GR. Health Measurement Scales: A Practical
23. Paiva CE, Barroso EM, Carneseca EC, et al. A critical analysis of test-
retest reliability in instrument validation studies of cancer patients under
Hill; 1978.
nutrition knowledge questionnaire for adults. J Nutr Educ Behav.
26. Deniz MS, Alsaffar AA. Assessing the validity and reliability of a
questionnaire on dietary fibre-related knowledge in a Turkish student
27. Maikranz V, Siebenhofer A, Ulrich LR, et al. Does a complex interven-
tion increase patient knowledge about oral anticoagulation? A cluster-
28. Winans AR, Rudd KM, Triller D. Assessing anticoagulation knowl-
dge in patients new to warfarin therapy. Ann Pharmacother.
29. Polek C, Hardie T. Warfarin use post hospitalization: pilot compara-
80–87.
30. Vormfeld SV, Abu Abed M, Hua TD, Schneider S, Friede T, Che-
ot JF. Educating orally anticoagulated patients in drug safety: a
cluster-randomized study in general practice. Dtsch Arztebl Int.
Supplementary materials

Patient questionnaire about blood thinner

Dear patients,

Thank you very much for participating in our survey. We prepared 15 questions about “new blood thinner”. Completing the questionnaire takes about 10 minutes.

Please answer the questions:

• By crossing the box □ with the correct answer
• Please do only cross one box per question.
• If you are sure, that you have answered the question correctly, please cross as well the box “I am sure” □ Yes.
• If you are not sure about your answer, or if you have guessed it, please cross the box “I am sure” □ No.

The pharmacist will answer your questions afterwards.

1. What is the name of your blood thinner?
2. How long do you have to take your blood thinner?
3. How often should you take your blood thinner?
4. What does your blood thinner help to prevent you from?
5. Imagine you are uncertain whether you have already taken your blood thinner or not. What are you going to do?
6. Imagine you have forgotten to take the last dose of your medication. What are you going to do?
7. Imagine you have taken double the dose of your tablets/capsules today by accident. What are you going to do?
8. Imagine you have taken your blood thinner 5 minutes ago and you had to vomit then. Does the blood thinner work less now?
9. Which is a frequent side effect of your blood thinner?
10. Which over the counter painkiller is the safest to take if you are also taking a blood thinner?
11. You would like to take an over the counter medicine, but you do not know if this medicine affects the way your blood thinner works. With whom do you confer this with best?
12. In which situation should you tell your doctor that you are taking a blood thinner?
13. In which situation should you contact your doctor right away or go to the emergency room?
14. How often should you see your doctor for a check-up if you are taking a blood thinner?
15. What should you always carry with you, when you are taking a blood thinner?

Thank you for your participation!

Figure S1 Questions of the KODOA-test translated to English (for informative purpose; the English version has not been validated).